147 related articles for article (PubMed ID: 14565655)
1. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
Sarris AH; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Younes A; Mesina O; Cabanillas F; Medeiros LJ; Samuels B
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
[TBL] [Abstract][Full Text] [Related]
3. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
Sarris AH; Phan A; Goy A; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Medeiros LJ; Samuels B; Mesina O; Bleyer AW; Cabanillas F
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):27-31. PubMed ID: 12199630
[TBL] [Abstract][Full Text] [Related]
5. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
Tobinai K; Hotta T; Saito H; Ohnishi K; Ohno R; Ogura M; Ariyoshi Y; Takeyama K; Kobayashi T; Ohashi Y; Shirakawa S
Jpn J Clin Oncol; 1996 Dec; 26(6):455-60. PubMed ID: 9001351
[TBL] [Abstract][Full Text] [Related]
6. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Cosetti M; Wexler LH; Calleja E; Trippett T; LaQuaglia M; Huvos AG; Gerald W; Healey JH; Meyers PA; Gorlick R
J Pediatr Hematol Oncol; 2002 Feb; 24(2):101-5. PubMed ID: 11990694
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Takagi T; Saotome T
Leuk Lymphoma; 2001 Aug; 42(4):577-86. PubMed ID: 11697485
[TBL] [Abstract][Full Text] [Related]
11. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
12. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
Sugiyama K; Omachi K; Fujiwara K; Saotome T; Mizunuma N; Takahashi S; Ito Y; Aiba K; Horikoshi N
Cancer; 2002 Feb; 94(3):594-600. PubMed ID: 11857289
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
[TBL] [Abstract][Full Text] [Related]
18. Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.
Urushihata K; Koizumi T; Kaneki T; Yamaguchi S; Fujimoto K; Kubo K
Intern Med; 2002 Aug; 41(8):648-50. PubMed ID: 12211535
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.
Chamberlain MC
J Neurooncol; 2002 Sep; 59(2):157-63. PubMed ID: 12241109
[TBL] [Abstract][Full Text] [Related]
20. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Ohtsu T; Sasaki Y; Igarashi T; Murayama T; Kobayashi Y; Tobinai K
Jpn J Clin Oncol; 1998 Aug; 28(8):502-6. PubMed ID: 9769785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
